Arthritis Clinic & Research Center, Peking University People's Hospital, Beijing, China.
Arthritis Institute, Peking University, Beijing, China.
Int J Rheum Dis. 2017 Nov;20(11):1612-1630. doi: 10.1111/1756-185X.13233. Epub 2017 Dec 5.
Numerous systematic reviews investigating the efficacy of platelet-rich plasma (PRP) in treating knee osteoarthritis (OA) have been recently published. The purpose of the present study was (1) to perform an overview of overlapping systematic reviews investigating PRP for knee OA via evaluating methodological quality and risk of bias of systematic reviews and (2) to provide recommendations through the best evidence.
A systematic search of systematic reviews published through Feb 2017 was conducted using the MEDLINE, EMBASE and Cochrane Library. The methodological quality and risk of bias of included systematic reviews were assessed by AMSTAR instrument and ROBIS tool respectively. Best evidence choice procedure was conducted according to the Jadad decision algorithm. The systematic reviews with high quality of methodology and low risk of bias were selected ultimately.
Ten systematic reviews were eligible for inclusion. The Jadad decision making tool suggested that the reviews with highest AMSTAR score should be selected. According to the ROBIS tool, there were 4 systematic reviews with low risk of bias and 6 with high risk of bias. As a result, two systematic reviews conducted by Dai et al and Meheux et al with highest AMSTAR score and low risk of bias were selected as the best evidence.
The present overview demonstrates that PRP is an effective intervention in treating knee OA without increased risk of adverse events. Therefore, the present conclusions may help decision makers interpret and choose PRP with more confidence.
最近发表了许多系统评价,研究富血小板血浆(PRP)治疗膝骨关节炎(OA)的疗效。本研究的目的是(1)通过评估系统评价的方法学质量和偏倚风险,对 PRP 治疗膝 OA 的重叠系统评价进行概述,(2)通过最佳证据提供建议。
通过 MEDLINE、EMBASE 和 Cochrane 图书馆,对截至 2017 年 2 月发表的系统评价进行了系统搜索。使用 AMSTAR 工具评估纳入系统评价的方法学质量和偏倚风险,使用 ROBIS 工具评估偏倚风险。根据 Jadad 决策算法进行最佳证据选择程序。最终选择方法学质量高、偏倚风险低的系统评价。
符合纳入标准的系统评价有 10 篇。Jadad 决策工具建议选择 AMSTAR 评分最高的综述。根据 ROBIS 工具,有 4 篇系统评价为低偏倚风险,6 篇为高偏倚风险。因此,选择 Dai 等人和 Meheux 等人的两篇 AMSTAR 评分最高、偏倚风险最低的系统评价作为最佳证据。
本综述表明,PRP 是治疗膝 OA 的有效干预措施,不会增加不良事件的风险。因此,本结论可以帮助决策者更有信心地解释和选择 PRP。